Good Newsletter. Looks like we are close to federally mandate...

Good Newsletter. Looks like we are close to federally mandate breast density scores in the US, this can only be a positive for Volpara and it continues to amaze me the number of academic and clinical trials their products are involved with, it is clear from a key opinion leaders viewpoint Hologics Quantra and the ICAD product are not serious density measurement competitors, that is before you add in all the other aspects of Volpara Enterprise and Live. Quantra is making a few moves in this direction but it seems that Hologics have neither the infrastructure or the inclination to really compete. It is probably the right move for them as they can capture some captive demand without having to offer a best in class product. In time Volpara would make a fantastic purchase for Hologics.